MedPath

Scandion Oncology A/S

Scandion Oncology A/S logo
🇩🇰Denmark
Ownership
Public
Established
2017-01-01
Employees
4
Market Cap
-
Website
http://www.scandiononcology.com

Clinical Trials

5

Active:3
Completed:0

Trial Phases

1 Phases

Phase 1:5

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials

Phase 1
5 (100.0%)

Clinical Trial to Investigate Safety, Tolerability and MTD for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients.

Phase 1
Conditions
Metastatic Pancreatic Adenocarcinoma
Inoperable Disease
Locally Advanced Pancreatic Adenocarcinoma
Localized Pancreatic Adenocarcinoma
Interventions
First Posted Date
2020-12-03
Last Posted Date
2021-12-29
Lead Sponsor
Scandion Oncology A/S
Target Recruit Count
18
Registration Number
NCT04652206
Locations
🇩🇰

Aalborg University Hospital, Aalborg, Denmark

🇩🇰

Odense Universitetshospital, Odense, Denmark

🇩🇪

Catholic Hospital Bochum - St. Josef-Hospital, Bochum, Germany

and more 1 locations

A Phase 2 Trial of SCO-101 in Combination With FOLFIRI for Patients With Metastatic Colorectal Cancer (mCRC) With Acquired Resistance to FOLFIRI

Phase 1
Conditions
Metastatic Colorectal Cancer
Interventions
Drug: FOLFIRI Protocol
First Posted Date
2020-01-30
Last Posted Date
2022-03-02
Lead Sponsor
Scandion Oncology A/S
Target Recruit Count
35
Registration Number
NCT04247256
Locations
🇩🇰

Aalborg Universitetshospital - Region Nordjylland, Aalborg, Denmark

🇩🇰

Herlev Hospital, Herlev, Denmark

🇩🇰

Hillerød Hospital, Hillerød, Denmark

and more 9 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.